SCHEMBL9844320

SCHEMBL9844320

Cc1ccc2nnc(-c3ccccc3)n2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.49
HSD17B10 Q99714 5/20 0.49
KMT2A Q03164 3/20 0.49
HPGD P15428 3/20 0.49
ALDH1A1 P00352 3/20 0.49
NPC1 O15118 2/20 0.49
TSHR P16473 2/20 0.49
RAB9A P51151 2/20 0.49
TP53 P04637 1/20 0.49
PKM P14618 1/20 0.49
CDK5 Q00535 1/20 0.49
CDK5R1 Q15078 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MAPK14 Q16539 1/20 0.48
ABL1 P00519 1/20 0.46
PDGFRA P16234 1/20 0.46
CSNK1A1 P48729 1/20 0.46
CDK7 P50613 1/20 0.46
BTK Q06187 1/20 0.46
MAP4K2 Q12851 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23547235 0.88 PIM1 (0.58) KDM4EHSD17B10KMT2AHPGDALDH1A1
SCHEMBL13757339 0.84 KDM4E (0.50) KDM4EHSD17B10HPGDALDH1A1TP53
SCHEMBL16331148 0.83 RET (0.66) KDM4EHSD17B10KMT2AMAPK14ABL1
SCHEMBL17055674 0.82 KDM4E (0.58) KDM4EHSD17B10HPGDALDH1A1TSHR
SCHEMBL12575452 0.80 BRD4 (0.47) KDM4EHSD17B10KMT2AHPGDALDH1A1
SCHEMBL16332036 0.80 MAPK14 (0.47) KDM4EHSD17B10KMT2AHPGDALDH1A1
SCHEMBL15007181 0.80 MAPK14 (0.60) KDM4EHSD17B10KMT2AHPGDMAPK14
SCHEMBL2302766 0.80 KDM4E (0.51) KDM4EHSD17B10KMT2AHPGDALDH1A1
SCHEMBL13757325 0.78 KDM4E (0.57) KDM4EHSD17B10HPGDALDH1A1SMN1; SMN2
SCHEMBL23733338 0.78 ABL1 (0.54) KDM4EHSD17B10KMT2AHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210238183-A1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS SUMITOMO PHARMA AMERICA, INC. 2021-08-05 US disclosed
EP-0441718-A1 Herbicidally active triazolopyridine compounds RHONE-POULENC AGROCHIMIE (FR) 1991-08-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238183-A1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS PIM1, PIM2, PIM3 KDM4E 1020/4885HSD17B10 4685/4885KMT2A 1046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.